血小板蛋白酶激活受体4的基因型和怀孕期间对阿司匹林的反应
Rupsa C Boelig1,2, James V Michael3, Antonios Tawk3
1Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
Blood vessels, thrombosis & hemostasis
|September 8, 2025
概括
孕妇中PAR4-Thr120基因型没有改变用PFA-100测量的阿司匹林反应. 然而,这种基因型与较高的先前早产率和在阿司匹林治疗期间减少的血栓糖抑制有关.
科学领域:
- 产科和妇科 产科和妇科
- 药物基因组学 药物基因组学
- 心血管研究研究心血管研究
背景情况:
- 在高风险怀孕中,阿司匹林对于预防妊娠前和早产至关重要.
- 血小板蛋白酶激活受体4 (PAR4) threonine 120 (Thr120) 等位基因是一种可能影响阿司匹林反应的激活变体.
- 了解对阿司匹林疗效的遗传影响对于优化妊娠结果至关重要.
研究的目的:
- 研究PAR4基因型,特别是Thr120等位基因对高风险妊娠中阿司匹林反应的影响.
- 评估PAR4基因型与关键围产期结局之间的关系.
- 为了评估阿司匹林在不同PAR4基因型的孕妇中的有效性.
主要方法:
- 122名高风险孕妇接受每天81毫克阿司匹林的前性队列研究.
- 血小板功能测定 (PFA-100) 在基线,早期随访和妊娠晚期测量的上腺素闭合时间.
- 对PAR4-Thr120等位基因的基因型定型和尿液中血栓糖度的分析.
主要成果:
- PAR4-Thr120同卵性个体的早产率明显更高 (50.0%与16.1%相比).
- 在多变量回归中,PAR4基因型和PFA-100阿司匹林反应之间没有发现显著的关联.
- 在同卵性个体中观察到较高的血栓素水平 (几何平均比,208) 和增加胎盘间性血栓的趋势.
结论:
- 在高风险怀孕中,PFA-100测量PAR4-Thr120基因型没有显著改变阿司匹林反应.
- PAR4-Thr120同卵性与早产史有关,可能表明尽管使用阿司匹林,但血栓糖抑制减少和胎盘血管病变风险增加.
- 需要进一步的研究来澄清PAR4基因型在怀孕和阿司匹林治疗中的临床影响.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Formation of the Platelet Plug
8.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
466
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
466
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K


